InsidersTradesSigma
Follow the 上海莱士 share price and the full insider trade history of the company, a listed issuer based in China. Shares are quoted on the CN market, under the supervision of SSE / SZSE (CSRC). Operating in the Health Care sector, 上海莱士 has published 6 insider filings. Market capitalisation: €32.3bn. The latest transaction was filed on 21 April 2026 (Purchase). Among the most active insiders: JUN XU. The full history is free.
6
Insider Decl.
n/a
Thresholds
€1m
6 ops.
Buy Volume
n/a
n/a
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 15,604 of 29,063 companies
50.0
score / 100
Value42
Quality58
FCF yld-2.2%
Earn yld4.8%
EV/EBITDA16.8x
ROE4.1%
Gross mgn37%
Net mgn21%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 April 2026
Declarations6 total
6 of 6 declarations
Acerca de 上海莱士
Shanghai Laishi es una empresa del sector de la salud y farmacéutico, que cotiza en el mercado XSHE. Se centra en el desarrollo y la producción de productos farmacéuticos innovadores.